CORRECTION article

Front. Pharmacol., 08 February 2021

Sec. Drugs Outcomes Research and Policies

Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.637775

Corrigendum: Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics

  • 1. National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

  • 2. Independent Medical Consultant, and Consultant, Pharmaceutical Medicine, Athens, Greece

  • 3. Consultants in Pharmaceutical Medicine, Dover Heights, Australia

  • 4. LIF, Stockholm, Sweden

  • 5. Independent Consultant, Basel, Switzerland

  • 6. Independent Researcher, Bellagio, Italy

  • 7. Pfizer Biopharmaceuticals Group, Dublin, Ireland

  • 8. Craveri Pharma, Buenos Aires, Argentina

  • 9. Cantonal Ethics Committee, Zurich, Switzerland

  • 10. Eli Lilly & Co., Lisbon, Portugal

  • 11. Nippon Medical School, Tokyo, Japan

  • 12. Ferozsons Laboratories Ltd, Karachi, Pakistan

  • 13. PPH Plus GmbH & Co. KG, Hochheim am Main, Germany

  • 14. IFAPP Academy, New York, NY, United States

  • 15. Semmelweis University, Budapest, Hunbary

In the original article, there were errors.

In the abstract, “(Declaration of Taipei)” was deleted; in the 1 Introduction section, “1948, in its second year” was changed to “in its second and third years”; in the 4 Individual Participant Data (IPD) Sharing and Trial Registration Requirement section, parenthesis before and after “Supplementary Material”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

JB is an employee of LIF; AC is an employee of Pfizer Biopharmaceuticals Group; LC is an employee of Craveri Pharma; LF is an employee of Eli Lilly & Co.; SN is an employee of Ferozsons Laboratories Ltd.; JS is an executive consultant of PPH plus GmbH & Co. KG, Hochheim am Main.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Summary

Keywords

research ethics, data science, medicines development, privacy protection, data sharing, declaration of Helsinki, declaration of Taipei

Citation

Kurihara C, Baroutsou V, Becker S, Brun J, Franke-Bray B, Carlesi R, Chan A, Collia LF, Kleist P, Laranjeira LF, Matsuyama K, Naseem S, Schenk J, Silva H, Kerpel-Fronius S and on behalf of Working Group on Ethics of the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (2021) Corrigendum: Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics. Front. Pharmacol. 11:637775. doi: 10.3389/fphar.2020.637775

Received

04 December 2020

Accepted

23 December 2020

Published

08 February 2021

Volume

11 - 2020

Edited and reviewed by

Joseph O. Fadare, Ekiti State University, Nigeria

Updates

Copyright

*Correspondence: Chieko Kurihara,

This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics